TY - JOUR
T1 - Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia
AU - Aguayo, Alvaro
AU - Cortes, Jorge
AU - Thomas, Deborah
AU - Pierce, Sherry
AU - Keating, Michael
AU - Kantarjian, Hagop
PY - 1999/10/1
Y1 - 1999/10/1
N2 - BACKGROUND. L-asparaginase in combination with methotrexate has synergistic antileukemic activity in a schedule-dependent fashion. A new preparation of L-asparaginase, polyethylene-glycol conjugated (PEG)- asparaginase, is a pharmacologically different formulation of L-asparaginase with distinct properties including a longer half-life and less immunogenic properties. METHODS. Patients with refractory or recurrent acute lymphoblastic leukemia (ALL) were treated with a combination of methotrexate (MTX), vincristine, PEG-asparaginase, and prednisone (MOAP). The treatment was comprised of MTX, 100 mg/m2 intravenously (i.v.), over 15 minutes on Days 1 and 14, PEG-asparaginase, 2500 IU/m2, with a maximum dose of 3750 IU i.v. approximately 4-6 hours after MTX on Days 1 and 14; vincristine, 1.4 mg/m2 (maximum dose, 2 mg) i.v., over 15 minutes on Days 1, 7, and 14; and prednisone, 200 mg daily orally, on Days 1-5 and 14-19. RESULTS. Thirty-two patients with a median age of 34 years (range, 20-74 years) were treated. Eight patients (25%) had ALL that was refractory to prior therapy and 24 patients (75%) had recurrent disease. Seven patients (22%) achieved a complete remission (CR). Five patients (16%) died early due to infections. Features associated with a poor response were high pretreatment lactate dehydrogenase levels and Philadelphia chromosome positive disease. The median duration of CR was 16 weeks and the overall median survival after MOAP therapy was 12 weeks. Anaphylactic reactions were not observed during MOAP combination therapy. CONCLUSIONS. MOAP is an active regimen in patients with refractory or recurrent ALL. This regimen is well tolerated and is not associated with allergic reactions. However, further studies regarding the pharmacologic interaction of MTX with PEG-asparaginase are needed to optimize this regimen.
AB - BACKGROUND. L-asparaginase in combination with methotrexate has synergistic antileukemic activity in a schedule-dependent fashion. A new preparation of L-asparaginase, polyethylene-glycol conjugated (PEG)- asparaginase, is a pharmacologically different formulation of L-asparaginase with distinct properties including a longer half-life and less immunogenic properties. METHODS. Patients with refractory or recurrent acute lymphoblastic leukemia (ALL) were treated with a combination of methotrexate (MTX), vincristine, PEG-asparaginase, and prednisone (MOAP). The treatment was comprised of MTX, 100 mg/m2 intravenously (i.v.), over 15 minutes on Days 1 and 14, PEG-asparaginase, 2500 IU/m2, with a maximum dose of 3750 IU i.v. approximately 4-6 hours after MTX on Days 1 and 14; vincristine, 1.4 mg/m2 (maximum dose, 2 mg) i.v., over 15 minutes on Days 1, 7, and 14; and prednisone, 200 mg daily orally, on Days 1-5 and 14-19. RESULTS. Thirty-two patients with a median age of 34 years (range, 20-74 years) were treated. Eight patients (25%) had ALL that was refractory to prior therapy and 24 patients (75%) had recurrent disease. Seven patients (22%) achieved a complete remission (CR). Five patients (16%) died early due to infections. Features associated with a poor response were high pretreatment lactate dehydrogenase levels and Philadelphia chromosome positive disease. The median duration of CR was 16 weeks and the overall median survival after MOAP therapy was 12 weeks. Anaphylactic reactions were not observed during MOAP combination therapy. CONCLUSIONS. MOAP is an active regimen in patients with refractory or recurrent ALL. This regimen is well tolerated and is not associated with allergic reactions. However, further studies regarding the pharmacologic interaction of MTX with PEG-asparaginase are needed to optimize this regimen.
KW - Acute lymphoblastic leukemia
KW - L-asparaginase
KW - Polyethylene-glycol conjugated (PEG)-asparaginase
KW - Recurrent
KW - Refractory
UR - http://www.scopus.com/inward/record.url?scp=0033214796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033214796&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0142(19991001)86:7<1203::AID-CNCR15>3.0.CO;2-3
DO - 10.1002/(SICI)1097-0142(19991001)86:7<1203::AID-CNCR15>3.0.CO;2-3
M3 - Article
C2 - 10506705
AN - SCOPUS:0033214796
SN - 0008-543X
VL - 86
SP - 1203
EP - 1209
JO - Cancer
JF - Cancer
IS - 7
ER -
